Phase 2 study of Bortezomib/dexamethasone w or w/o Elotuzumab in pts. with relapsed/refractory MM

Grants and Contracts Details

Description

CONFIDENTIAL: Site was not selected for this trial.
StatusFinished
Effective start/end date7/1/1210/31/12

Funding

  • Parexel International Co: $8,600.00

Fingerprint

Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.